Targeted therapies for myeloproliferative neoplasms | Biomarker Research | Full Text

Targeted therapies for myeloproliferative neoplasms | Biomarker Research | Full Text

Targeted therapies for myeloproliferative neoplasms

The discovery of JAK2V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultim...

Authors:Bing Li, Raajit K. Rampal and Zhijian Xiao

Citation:Biomarker Research 2019 7:15

Content type:Review

Published on: 16 July 2019

• ViewFull Text
 
• ViewPDF